Understanding the Rising Costs of Opioid Spending in US Healthcare

The opioid crisis has been a significant public health challenge in the United States, affecting millions of individuals and communities across the country. As the crisis has evolved, so has the economic impact, with opioid spending becoming a growing concern. In this blog, we will examine the trends and statistics of opioid spending in the US from 2017 to the present, shedding light on the increasing costs associated with this complex issue.

Overview of Opioid Spending in the US:

The cost of the opioid crisis in the US has been staggering. According to the National Institute on Drug Abuse (NIDA), the estimated economic burden of prescription opioid misuse, abuse, and overdose in the US was $78.5 billion in 2013, with the cost of heroin misuse and overdose accounting for an additional $27 billion. Since then, opioid spending has continued to rise, and it has become a multifaceted problem that encompasses healthcare expenses, law enforcement costs, lost productivity, and other related economic impacts.

Healthcare Expenses

A significant portion of opioid spending in the US is associated with healthcare expenses. The Centers for Disease Control and Prevention (CDC) estimates that the total economic burden of prescription opioid misuse alone, including healthcare costs, lost productivity, and criminal justice involvement, exceeded $500 billion in 2015. This includes costs associated with opioid-related hospitalizations, emergency department visits, and outpatient services.



In recent years, the cost of treating opioid-related health issues has continued to rise. A study published in the journal Medical Care in 2020 found that the average annual cost of opioid-related hospitalizations increased by 64% from 2005 to 2016, with the total cost reaching $15 billion in 2016. The same study also found that the average cost of opioid-related emergency department visits increased by 99% during the same period, reaching $5.1 billion in 2016.

Additionally, the cost of prescription opioids themselves has also been a significant contributor to opioid spending. According to a report by the US Senate Committee on Homeland Security and Government Affairs, spending on prescription opioids in the US increased from $8.6 billion in 2001 to $24.4 billion in 2015, a nearly threefold increase. Although there has been a decline in the number of opioid prescriptions since the peak in 2012, the cost per prescription has increased, contributing to the overall rise in opioid spending.

Law Enforcement Access

Another aspect of opioid spending in the US is the cost associated with law enforcement efforts to combat the crisis. This includes funding for federal, state, and local law enforcement agencies involved in investigations, arrests, prosecutions, and other activities related to opioid trafficking and distribution.



According to a report by the US Department of Justice, the estimated cost of federal law enforcement efforts related to opioids was $1.5 billion in fiscal year 2019. This included funding for agencies such as the Drug Enforcement Administration (DEA), the Federal Bureau of Investigation (FBI), and the Office of National Drug Control Policy (ONDCP). In addition, state and local law enforcement agencies also incur significant costs in their efforts to combat opioid trafficking and distribution within their jurisdictions.

Other Economic Factors

In addition to healthcare expenses, law enforcement costs, and lost productivity, the opioid crisis has other economic impacts. These include increased spending on addiction treatment programs, social services, and child welfare services, as well as the costs associated with caring for infants born with neonatal abstinence syndrome (NAS), a condition that occurs when babies are exposed to opioids during pregnancy.

The cost of addiction treatment programs has been on the rise, with increased demand for services as more individuals seek help for opioid addiction. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), in 2019, an estimated 2.0 million Americans needed treatment for opioid use disorder, but only 18.1% received it. The cost of providing evidence-based treatments such as medication-assisted treatment (MAT), counseling, and other supportive services can add up, contributing to the overall opioid spending.

The opioid crisis has also strained social services and child welfare systems, as many individuals struggling with opioid addiction require assistance with housing, employment, and childcare. This has resulted in increased spending on social services programs and child welfare services to ensure the safety and well-being of affected individuals and their families.

Furthermore, caring for infants born with NAS has become a significant cost burden for hospitals and healthcare systems. A study published in the Journal of Perinatology in 2019 estimated that the average hospital cost for a newborn with NAS was $14,087, compared to $1,566 for a newborn without NAS. This includes the costs associated with extended hospital stays, medications, and supportive care for these vulnerable infants.



Lost Productivity Due to Opioid Crisis

Lost productivity due to opioid misuse and addiction has also been a significant factor in opioid spending in the US. The impact of opioid addiction on the workforce has resulted in increased absenteeism, reduced productivity, and increased healthcare utilization, all of which have economic consequences.



A study published in the Journal of Occupational and Environmental Medicine in 2017 estimated that the total cost of lost productivity due to opioid misuse in the US was $25.6 billion in 2013. This includes costs associated with absenteeism, presenteeism (when employees are at work but not fully productive), disability claims, and premature death. The same study projected that by 2019, the cost of lost productivity due to opioid misuse could exceed $45 billion annually.

Furthermore, the opioid crisis has had a significant impact on labor force participation, as individuals struggling with opioid addiction may be unable to work or may drop out of the labor force altogether. This has long-term economic consequences, as it reduces the overall productivity and economic output of the country.

Overall Trends in Opioid Spending

The trends in opioid spending in the US from 2017 to the present have shown a steady increase, reflecting the ongoing severity of the opioid crisis and its economic impact. While there have been efforts to curb opioid prescribing practices, increase access to addiction treatment, and improve law enforcement efforts, the economic burden of the crisis continues to rise.

According to data from the IQVIA Institute for Human Data Science, total spending on prescription opioids in the US reached $11.4 billion in 2018, an increase of 5% compared to the previous year. This increase was largely driven by higher costs per prescription, as the number of opioid prescriptions continued to decline. Additionally, spending on addiction treatment medications, such as buprenorphine and naltrexone, also increased, reflecting the growing demand for evidence-based treatments for opioid use disorder.



The costs associated with opioid-related health issues, including hospitalizations, emergency department visits, and outpatient services, have also continued to rise. According to data from the Agency for Healthcare Research and Quality (AHRQ), the total cost of opioid-related hospital stays in the US increased from $15 billion in 2010 to $29.7 billion in 2015, a nearly two-fold increase in just five years. The cost of emergency department visits related to opioids also increased from $1.4 billion in 2005 to $3.1 billion in 2015, a more than two-fold increase.

Law enforcement costs related to opioids have also continued to rise, reflecting the ongoing efforts to combat the trafficking and distribution of opioids. The federal government has allocated additional funding to support law enforcement efforts, including the Comprehensive Addiction and Recovery Act (CARA) and the Opioid Response Grants from the Substance Abuse and Mental Health Services Administration (SAMHSA). These efforts have included initiatives such as increased surveillance of opioid prescribing practices, crackdown on illicit opioid trafficking, and diversion prevention programs. However, despite these efforts, the economic burden of law enforcement costs associated with the opioid crisis has continued to rise.

Moreover, the economic impact of the opioid crisis has been particularly devastating for some regions of the US. Rural areas, in particular, have been hit hard by the opioid epidemic, with higher rates of opioid-related deaths, hospitalizations, and other related costs. These communities often face additional challenges in terms of access to healthcare, addiction treatment services, and economic opportunities, which further exacerbate the economic burden of the opioid crisis.

In recent years, there have been efforts to address the opioid crisis through various strategies, including increased access to addiction treatment, expansion of harm reduction services, and efforts to promote safer opioid prescribing practices. The Comprehensive Addiction and Recovery Act (CARA), signed into law in 2016, aims to strengthen prevention, treatment, and recovery efforts, and the SUPPORT for Patients and Communities Act, signed into law in 2018, includes provisions to combat the opioid crisis through a multi-faceted approach. These efforts have shown promise in reducing opioid prescriptions, increasing access to addiction treatment, and reducing opioid-related deaths in some areas.

However, despite these efforts, the economic burden of the opioid crisis continues to be a significant challenge for the US healthcare system, law enforcement agencies, employers, and communities at large. The costs associated with opioid-related health issues, addiction treatment programs, law enforcement efforts, lost productivity, and other economic impacts continue to rise, posing significant challenges to individuals, families, and communities across the nation.

Conclusion

The opioid crisis in the US has had a profound economic impact, with significant costs associated with healthcare expenses, law enforcement efforts, lost productivity, and other economic impacts. The rising opioid spending from 2017 to the present reflects the ongoing severity of the crisis and the need for continued efforts to combat this epidemic. While there have been some efforts to address the issue, the economic burden of the opioid crisis remains a significant challenge for the healthcare system, law enforcement agencies, employers, and communities.



To address the opioid crisis and reduce its economic impact, a multi-faceted approach is needed. This includes efforts to promote safer opioid prescribing practices, increase access to evidence-based addiction treatment, expand harm reduction services, improve surveillance and monitoring of opioid prescribing, and provide support and resources for individuals struggling with opioid addiction and their families. Additionally, addressing the social determinants of health, such as poverty, unemployment, and lack of access to education and economic opportunities, is critical to addressing the root causes of the opioid crisis and reducing its economic burden.

Furthermore, there is a need for continued research and data collection to better understand the economic impact of the opioid crisis, monitor trends in opioid spending, and evaluate the effectiveness of interventions and policies aimed at addressing the issue. This can inform evidence-based strategies and policies to combat the opioid crisis and reduce its economic impact.

In conclusion, the opioid crisis in the US has had significant economic consequences, with rising opioid spending from 2017 to the present reflecting the ongoing severity of the crisis. Addressing the economic impact of the opioid crisis requires a comprehensive and multi-faceted approach that involves efforts to prevent opioid misuse, increase access to addiction treatment, improve law enforcement efforts, and address the social determinants of health. By taking a comprehensive approach and implementing evidence-based strategies, we can work towards reducing the economic burden of the opioid crisis and improving the health and well-being of individuals, families, and communities across the nation.

References:

• Centers for Disease Control and Prevention. (CDC). (2021). Opioid Overdose. Retrieved from https://www.cdc.gov/drugoverdose/index.html
• Florence, C. S., Zhou, C., Luo, F., & Xu, L. (2016). The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Medical care, 54(10), 901-906.
• National Institute on Drug Abuse (NIDA). (2020). Opioid Overdose Crisis. Retrieved from https://www.drugabuse.gov/drug-topics/opioids/opioid-overdose-crisis
• Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016). Increases in Drug and Opioid-Involved Overdose Deaths—United States, 2010-2015. MMWR. Morbidity and mortality weekly report, 65(50-51), 1445-1452.
• Substance Abuse and Mental Health Services Administration (SAMHSA). (2021). Opioid Crisis. Retrieved from https://www.samhsa.gov/find-help/national-helpline
• U.S. Department of Veterans Affairs (VA). (2021). Opioid Overdose Education and Naloxone Distribution (OEND). Retrieved from https://www.research.va.gov/topics/opioid.cfm
• U.S. Senate Committee on Health, Education, Labor, and Pensions. (2018). The Opioid Crisis: The Role of Technology and Data in Preventing and Treating Addiction. Retrieved from https://www.help.senate.gov/hearings/the-opioid-crisis-the-role-of-technology-and-data-in-preventing-and-treating-addiction
• White House. (2021). National Drug Control Strategy. Retrieved from https://www.whitehouse.gov/ondcp/national-drug-control-strategy/
• World Health Organization (WHO). (2019). Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK536227/
• Zhang, Y., Baicker, K., & Newhouse, J. P. (2018). Geographic variation in the opioid crisis: implications for public health policy. The Milbank Quarterly, 96(4), 697-723.
• Zhang, Y., Faries, D. E., & Baicker, K. (2018). The Economic Burden of the Opioid Epidemic on States: The Case of Medicaid. American Journal of Managed Care, 24(1), 11-17.
• Zuckerman, S., Goin, D. E., Shih, A., & Tai-Seale, M. (2018). The Economics of Opioid Prescribing: Insights from the Medicare Part D Data. National Institute for Health Care Management. Retrieved from https://nihcm.org/publications/the-economics-of-opioid-prescribing-insights-from-the-medicare-part-d-data
• Zuckerman, S., Alexander, G. C., & Balmert, L. C. (2019). Prescription opioids: What you need to know. Journal of General Internal Medicine, 34(5), 796-802.
• Zylla, D., Jones, M. A., & Ruoho, A. E. (2015). Insight into the impact of sigma receptors upon neuropathic pain. European journal of pharmacology, 716, 58-66.
• Opioid Crisis Fast Facts. (2021). CNN Health. Retrieved from https://www.cnn.com/2017/09/18/health/opioid-crisis-fast-facts/index.html
• Opioid Epidemic Statistics. (2021). American Society of Addiction Medicine. Retrieved from https://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdf
• Anderson, G. (2019). Prescription opioid spending and the role of insurance: evidence from the US Medicare population. Journal of health economics, 65, 153-162.
• National Conference of State Legislatures (NCSL). (2021). Prescription Drug Monitoring Programs. Retrieved from https://www.ncsl.org/research/health/prescription-drug-monitoring-programs.aspx
• The Opioid Crisis Response Act (OCRA). (2018). U.S. Department of Health and Human Services. Retrieved from https://www.hhs.gov/opioids/about-the-epidemic/hhs-response/index.html
• National Institute on Drug Abuse (NIDA). (2020). Overdose Death Rates. Retrieved from https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates
• National Institute on Drug Abuse (NIDA). (2019). Prescription Opioids DrugFacts. Retrieved from https://www.drugabuse.gov/publications/drugfacts/prescription-opioids
• National Institute on Drug Abuse (NIDA). (2018). America’s Addiction to Opioids: Heroin and Prescription Drug Abuse. Retrieved from https://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2018/americas-addiction-to-opioids-heroin-prescription-drug-abuse
• Centers for Disease Control and Prevention (CDC). (2021). Opioid Overdose: Understanding the Epidemic. Retrieved from https://www.cdc.gov/drugoverdose/epidemic/index.html
• Kiang, M. V., Humphreys, K., Cullen, M. R., & Basu, S. (2019). Opioid prescribing patterns among medical providers in the United States, 2003-17: retrospective, observational study. Bmj, 365, l5142.
• Kertesz, S. G., & Gordon, A. J. (2021). A crisis of opioids and the limits of prescription control: United States. In International Handbook on Adolescent Drug Use Prevention (pp. 213-227). Springer.
• U.S. Department of Health and Human Services (HHS). (2018). HHS Acting Secretary Declares Public Health Emergency to Address National Opioid Crisis. Retrieved from https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html